MannKind Corporation reduces debt by $194 million and increases cash position to over $180 million through note exchanges.Quiver AI SummaryMannKind Corporation has announced a significant reduction in...
MannKind plans FDA meeting for potential Afrezza supplemental application after positive Phase 3 diabetes study results in youth.Quiver AI SummaryMannKind Corporation announced today that it plans to meet...
MannKind's Afrezza inhaled insulin approved in India for diabetes treatment, expected to ship by end of 2025.Quiver AI SummaryMannKind Corporation has announced that India's Central Drugs Standard Control...
This milestone adds India to the list of countries where Afrezza is approved, joining the United States and Brazil.
Steven B. Binder, a director at $MNKD ($MNKD), sold 67,536 shares of the company on 11-22-2024. We received data on the trade from a recent SEC filing. This was a sale of approximately 5.9% of their shares....
MNKD earnings call for the period ending September 30, 2024.